Skip to main content
Erschienen in: Rheumatology International 5/2015

01.05.2015 | Original Article - Cases with a Message

Osseous sarcoidosis: a case series

verfasst von: Halyna Kuzyshyn, David Feinstein, Sharon L. Kolasinski, Hala Eid

Erschienen in: Rheumatology International | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Sarcoidosis is an inflammatory disorder characterized by noncaseating granulomas infiltrating affected organs. Any organ system can be involved, and more than 90 % of patients have a primary pulmonary manifestation. The incidence of radiographically evident bone involvement has been reported over a wide range: from 3 to 39 % depending on the population studied and imaging modalities used. Any bone may be affected in osseous sarcoidosis. Bilateral involvement of the phalanges of the hand and feet is most common. However, reports of long bone, skull, rib and vertebral involvement have appeared. To date, there are no specific tools for the assessment of skeletal disease activity in sarcoidosis. Plain radiograph picks lesions in the small bones of hands and feet greater than does in other bones. Bone scan is useful for defining the extent of the skeletal disease and bone marrow involvement. Magnetic resonance imaging usually demonstrates multifocal lesions within the vertebrae that are hypointense on T1-weighted images and hyperintense on T2-weighted images. In cases of multifocal bone lesions and an established diagnosis of sarcoidosis, a diagnosis of bone sarcoidosis should be considered in the differential diagnosis. Optimal treatment of osseous sarcoidosis remains controversial. We present five cases of multisystem sarcoidosis with skeletal involvement including long bones and vertebrae and a description of immunosuppressive therapies used in our patients. A literature review highlighting the diagnostic approach using radiographic imaging, as well as treatment strategies, is provided.
Literatur
1.
Zurück zum Zitat James DG, Neville E, Siltzbach LE (1976) A worldwide review of sarcoidosis. Ann NY Acad Sci 278:321–334CrossRefPubMed James DG, Neville E, Siltzbach LE (1976) A worldwide review of sarcoidosis. Ann NY Acad Sci 278:321–334CrossRefPubMed
2.
Zurück zum Zitat Shorr AF, Murphy FT, Gilliland WR, Hnatiuk W (2000) Osseous disease in patients with pulmonary sarcoidosis and musculoskeletal symptoms. Respir Med 94(3):228–232CrossRefPubMed Shorr AF, Murphy FT, Gilliland WR, Hnatiuk W (2000) Osseous disease in patients with pulmonary sarcoidosis and musculoskeletal symptoms. Respir Med 94(3):228–232CrossRefPubMed
3.
Zurück zum Zitat Chatham W (2010) Rheumatic manifestations of systemic disease: sarcoidosis. Curr Opin Rheumatol 22(1):85–90CrossRefPubMed Chatham W (2010) Rheumatic manifestations of systemic disease: sarcoidosis. Curr Opin Rheumatol 22(1):85–90CrossRefPubMed
4.
Zurück zum Zitat Ugwonali OF, Parisien M, Nickerson KG, Scully B, Ristic S, Strauch RJ (2005) Osseous sarcoidosis of the hand: pathologic analysis and review of the literature. J Hand Surg Am 30(4):854–858CrossRefPubMed Ugwonali OF, Parisien M, Nickerson KG, Scully B, Ristic S, Strauch RJ (2005) Osseous sarcoidosis of the hand: pathologic analysis and review of the literature. J Hand Surg Am 30(4):854–858CrossRefPubMed
5.
Zurück zum Zitat Talmi D, Smith S, Mulligan ME (2008) Central skeletal sarcoidosis mimicking metastatic disease. Skeletal Radiol 37(8):757–761CrossRefPubMed Talmi D, Smith S, Mulligan ME (2008) Central skeletal sarcoidosis mimicking metastatic disease. Skeletal Radiol 37(8):757–761CrossRefPubMed
6.
Zurück zum Zitat Waanders F, van Hengel P, Krikke A, Wesseling J, Nieboer P (2006) Sarcoidosis mimicking metastatic disease: a case report and review of the literature. Neth J Med 64(9):342–345PubMed Waanders F, van Hengel P, Krikke A, Wesseling J, Nieboer P (2006) Sarcoidosis mimicking metastatic disease: a case report and review of the literature. Neth J Med 64(9):342–345PubMed
7.
Zurück zum Zitat Fisher AJ, Gilula LA, Kyriakos M, Holzaepfel CD (1999) MR imaging changes of lumbar vertebral sarcoidosis. AJR Am J Roentgenol 173(2):354–356CrossRefPubMed Fisher AJ, Gilula LA, Kyriakos M, Holzaepfel CD (1999) MR imaging changes of lumbar vertebral sarcoidosis. AJR Am J Roentgenol 173(2):354–356CrossRefPubMed
8.
Zurück zum Zitat Lisle D, Mitchell K, Crouch M, Windsor M (2004) Sarcoidosis of the thoracic and lumbar spine: imaging findings with an emphasis on magnetic resonance imaging. Australas Radiol 48(3):404–407CrossRefPubMed Lisle D, Mitchell K, Crouch M, Windsor M (2004) Sarcoidosis of the thoracic and lumbar spine: imaging findings with an emphasis on magnetic resonance imaging. Australas Radiol 48(3):404–407CrossRefPubMed
9.
Zurück zum Zitat Poyanli A, Poyanli O, Sencer S, Akan K, Sayrak H, Acunaş B (2000) Vertebral sarcoidosis: imaging findings. Eur Radiol 10(1):92–94CrossRefPubMed Poyanli A, Poyanli O, Sencer S, Akan K, Sayrak H, Acunaş B (2000) Vertebral sarcoidosis: imaging findings. Eur Radiol 10(1):92–94CrossRefPubMed
10.
Zurück zum Zitat Rúa-Figueroa I, Gantes MA, Erausquin C, Mhaidli H, Montesdeoca A (2002) Vertebral sarcoidosis: clinical and imaging findings. Semin Arthritis Rheum 31(5):346–352CrossRefPubMed Rúa-Figueroa I, Gantes MA, Erausquin C, Mhaidli H, Montesdeoca A (2002) Vertebral sarcoidosis: clinical and imaging findings. Semin Arthritis Rheum 31(5):346–352CrossRefPubMed
11.
Zurück zum Zitat Binicier O, Sari I, Sen G, Onen F, Akkoc N, Manisali M, Akar S (2009) Axial sarcoidosis mimicking radiographic sacroiliitis. Rheumatol Int 29(3):343–345CrossRefPubMed Binicier O, Sari I, Sen G, Onen F, Akkoc N, Manisali M, Akar S (2009) Axial sarcoidosis mimicking radiographic sacroiliitis. Rheumatol Int 29(3):343–345CrossRefPubMed
12.
Zurück zum Zitat Yaghmai I (1983) Radiographic, angiographic and radionuclide manifestations of osseous sarcoidosis. RadioGraphics 3(3):375–396CrossRef Yaghmai I (1983) Radiographic, angiographic and radionuclide manifestations of osseous sarcoidosis. RadioGraphics 3(3):375–396CrossRef
13.
Zurück zum Zitat Mostard RL, Prompers L, Weijers RE, van Kroonenburgh MJ, Wijnen PA, Geusens PP, Drent M (2012) F-18 FDG PET/CT for detecting bone and bone marrow involvement in sarcoidosis patients. Clin Nucl Med 37(1):21–25CrossRefPubMed Mostard RL, Prompers L, Weijers RE, van Kroonenburgh MJ, Wijnen PA, Geusens PP, Drent M (2012) F-18 FDG PET/CT for detecting bone and bone marrow involvement in sarcoidosis patients. Clin Nucl Med 37(1):21–25CrossRefPubMed
14.
Zurück zum Zitat Mostard RL, Vöö S, van Kroonenburgh MJ, Verschakelen JA, Wijnen PA, Nelemans PJ, Erckens RJ, Drent M (2011) Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis. Respir Med 105(12):1917–1924CrossRefPubMed Mostard RL, Vöö S, van Kroonenburgh MJ, Verschakelen JA, Wijnen PA, Nelemans PJ, Erckens RJ, Drent M (2011) Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis. Respir Med 105(12):1917–1924CrossRefPubMed
15.
Zurück zum Zitat Sun SS, Tsai SC, Hung CJ, Tsai PP, Kao CH (2001) Tc-99m MDP and Ga-67 citrate scintigraphic findings in sarcoidosis with osseous involvement. Clin Nucl Med 26(5):472–473CrossRefPubMed Sun SS, Tsai SC, Hung CJ, Tsai PP, Kao CH (2001) Tc-99m MDP and Ga-67 citrate scintigraphic findings in sarcoidosis with osseous involvement. Clin Nucl Med 26(5):472–473CrossRefPubMed
16.
Zurück zum Zitat Moore SL, Kransdorf MJ, Schweitzer ME, Murphey MD, Babb JS (2012) Can sarcoidosis and metastatic bone lesions be reliably differentiated on routine MRI? AJR Am J Roentgenol 198(6):1387–1393CrossRefPubMed Moore SL, Kransdorf MJ, Schweitzer ME, Murphey MD, Babb JS (2012) Can sarcoidosis and metastatic bone lesions be reliably differentiated on routine MRI? AJR Am J Roentgenol 198(6):1387–1393CrossRefPubMed
17.
Zurück zum Zitat Moore SL, Teirstein AE (2003) Musculoskeletal sarcoidosis: spectrum of appearances at MR imaging. Radiographics 23(6):1389–1399CrossRefPubMed Moore SL, Teirstein AE (2003) Musculoskeletal sarcoidosis: spectrum of appearances at MR imaging. Radiographics 23(6):1389–1399CrossRefPubMed
18.
Zurück zum Zitat Moore SL, Teirstein A, Golimbu C (2005) MRI of sarcoidosis patients with musculoskeletal symptoms. AJR Am J Roentgenol 185(1):154–159CrossRefPubMed Moore SL, Teirstein A, Golimbu C (2005) MRI of sarcoidosis patients with musculoskeletal symptoms. AJR Am J Roentgenol 185(1):154–159CrossRefPubMed
19.
Zurück zum Zitat Johns CJ, Michele TM (1999) The clinical management of sarcoidosis. A 50-year experience at the Johns Hopkins Hospital. Medicine (Baltimore) 78(2):65–111CrossRef Johns CJ, Michele TM (1999) The clinical management of sarcoidosis. A 50-year experience at the Johns Hopkins Hospital. Medicine (Baltimore) 78(2):65–111CrossRef
20.
Zurück zum Zitat Johnson AK, Johnson JM, Ames E, Filippi C (2012) Spontaneous clinical and radiological resolution of vertebral sarcoidosis: a case report. Spine (Phila Pa 1976) 37(6):E414–E416CrossRef Johnson AK, Johnson JM, Ames E, Filippi C (2012) Spontaneous clinical and radiological resolution of vertebral sarcoidosis: a case report. Spine (Phila Pa 1976) 37(6):E414–E416CrossRef
21.
Zurück zum Zitat Salmon JH, Perotin JM, Direz G, Brochot P, Laredo JD, Eschard JP (2013) Vertebral sarcoidosis. Spontaneous favorable outcome: a case report and literature review. Rev Med Interne 34(1):42–46CrossRefPubMed Salmon JH, Perotin JM, Direz G, Brochot P, Laredo JD, Eschard JP (2013) Vertebral sarcoidosis. Spontaneous favorable outcome: a case report and literature review. Rev Med Interne 34(1):42–46CrossRefPubMed
22.
Zurück zum Zitat Shorr AF, Murphy FT, Kelly WF, Kaplan KJ, Gilliland WR, Shapeero LG (1998) Osseous sarcoidosis clinical, radiographic, and therapeutic observations. J Clin Rheumatol 4(4):186–192CrossRefPubMed Shorr AF, Murphy FT, Kelly WF, Kaplan KJ, Gilliland WR, Shapeero LG (1998) Osseous sarcoidosis clinical, radiographic, and therapeutic observations. J Clin Rheumatol 4(4):186–192CrossRefPubMed
23.
Zurück zum Zitat Wilcox A, Bharadwaj P, Sharma OP (2000) Bone sarcoidosis. Curr Opin Rheumatol 12(4):321–330CrossRefPubMed Wilcox A, Bharadwaj P, Sharma OP (2000) Bone sarcoidosis. Curr Opin Rheumatol 12(4):321–330CrossRefPubMed
24.
Zurück zum Zitat Mitchell DN (1998) Sarcoidosis with skeletal involvement. In: Klippel JH, Dieppe PA (eds) Rheumatology. Mosby International, London, pp 26.1–26.8 Mitchell DN (1998) Sarcoidosis with skeletal involvement. In: Klippel JH, Dieppe PA (eds) Rheumatology. Mosby International, London, pp 26.1–26.8
25.
Zurück zum Zitat Maña J, Gómez-Vaquero C, Dorca J, Pujol R (1999) Vertebral and rib sarcoidosis: long-term clinical remission with methotrexate. Clin Rheumatol 18(6):492–494CrossRefPubMed Maña J, Gómez-Vaquero C, Dorca J, Pujol R (1999) Vertebral and rib sarcoidosis: long-term clinical remission with methotrexate. Clin Rheumatol 18(6):492–494CrossRefPubMed
26.
Zurück zum Zitat Sakellariou GT, Anastasilakis AD, Karanikolas D, Vounotrypidis P, Berberidis C (2013) Central skeletal sarcoidosis: a case report with sustained remission only on methotrexate, and a literature review on the imaging approach, treatment, and assessment of disease activity. Mod Rheumatol 23(1):175–181CrossRefPubMed Sakellariou GT, Anastasilakis AD, Karanikolas D, Vounotrypidis P, Berberidis C (2013) Central skeletal sarcoidosis: a case report with sustained remission only on methotrexate, and a literature review on the imaging approach, treatment, and assessment of disease activity. Mod Rheumatol 23(1):175–181CrossRefPubMed
27.
Zurück zum Zitat Kaye O, Palazzo E, Grossin M, Bourgeois P, Kahn MF, Malaise MG (1995) Low-dose methotrexate: an effective corticosteroid-sparing agent in the musculoskeletal manifestations of sarcoidosis. Br J Rheumatol 34(7):642–644CrossRefPubMed Kaye O, Palazzo E, Grossin M, Bourgeois P, Kahn MF, Malaise MG (1995) Low-dose methotrexate: an effective corticosteroid-sparing agent in the musculoskeletal manifestations of sarcoidosis. Br J Rheumatol 34(7):642–644CrossRefPubMed
28.
Zurück zum Zitat Lower EE, Baughman RP (1990) The use of low dose methotrexate in refractory sarcoidosis. Am J Med Sci 299(3):153–157CrossRefPubMed Lower EE, Baughman RP (1990) The use of low dose methotrexate in refractory sarcoidosis. Am J Med Sci 299(3):153–157CrossRefPubMed
29.
Zurück zum Zitat Vucinic VM (2002) What is the future of methotrexate in sarcoidosis? A study and review. Curr Opin Pulm Med 8(5):470–476CrossRefPubMed Vucinic VM (2002) What is the future of methotrexate in sarcoidosis? A study and review. Curr Opin Pulm Med 8(5):470–476CrossRefPubMed
30.
Zurück zum Zitat Agostini C, Adami F, Semenzato G (2000) New pathogenetic insights into the sarcoid granuloma. Curr Opin Rheumatol 12(1):71–76CrossRefPubMed Agostini C, Adami F, Semenzato G (2000) New pathogenetic insights into the sarcoid granuloma. Curr Opin Rheumatol 12(1):71–76CrossRefPubMed
31.
Zurück zum Zitat Semenzato G, Pezzutto A, Chilosi M, Pizzolo G (1982) Redistribution of T lymphocytes in the lymph nodes of patients with sarcoidosis. N Engl J Med 306(1):48–49CrossRefPubMed Semenzato G, Pezzutto A, Chilosi M, Pizzolo G (1982) Redistribution of T lymphocytes in the lymph nodes of patients with sarcoidosis. N Engl J Med 306(1):48–49CrossRefPubMed
32.
Zurück zum Zitat Kasahara K, Kobayashi K, Shikama Y, Yoneya I, Kaga S, Hashimoto M, Odagiri T, Soejima K, Ide H, Takahashi T et al (1989) The role of monokines in granuloma formation in mice: the ability of interleukin 1 and tumor necrosis factor-alpha to induce lung granulomas. Clin Immunol Immunopathol 51(3):419–425CrossRefPubMed Kasahara K, Kobayashi K, Shikama Y, Yoneya I, Kaga S, Hashimoto M, Odagiri T, Soejima K, Ide H, Takahashi T et al (1989) The role of monokines in granuloma formation in mice: the ability of interleukin 1 and tumor necrosis factor-alpha to induce lung granulomas. Clin Immunol Immunopathol 51(3):419–425CrossRefPubMed
33.
Zurück zum Zitat Bargagli E, Mazzi A, Rottoli P (2008) Markers of inflammation in sarcoidosis: blood, urine, BAL, sputum, and exhaled gas. Clin Chest Med 29(3):445–458CrossRefPubMed Bargagli E, Mazzi A, Rottoli P (2008) Markers of inflammation in sarcoidosis: blood, urine, BAL, sputum, and exhaled gas. Clin Chest Med 29(3):445–458CrossRefPubMed
34.
Zurück zum Zitat Shigehara K, Shijubo N, Ohmichi M, Takahashi R, Kon S, Okamura H, Kurimoto M, Hiraga Y, Tatsuno T, Abe S, Sato N (2001) IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs. J Immunol 166(1):642–649CrossRefPubMed Shigehara K, Shijubo N, Ohmichi M, Takahashi R, Kon S, Okamura H, Kurimoto M, Hiraga Y, Tatsuno T, Abe S, Sato N (2001) IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs. J Immunol 166(1):642–649CrossRefPubMed
35.
Zurück zum Zitat Elliott M, Benson J, Blank M, Brodmerkel C, Baker D, Sharples KR, Szapary P (2009) Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases. Ann NY Acad Sci 1182:97–110CrossRefPubMed Elliott M, Benson J, Blank M, Brodmerkel C, Baker D, Sharples KR, Szapary P (2009) Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases. Ann NY Acad Sci 1182:97–110CrossRefPubMed
36.
Zurück zum Zitat Larousserie F, Pflanz S, Coulomb-L’Herminé A, Brousse N, Kastelein R, Devergne O (2004) Expression of IL-27 in human Th1-associated granulomatous diseases. J Pathol 202(2):164–171CrossRefPubMed Larousserie F, Pflanz S, Coulomb-L’Herminé A, Brousse N, Kastelein R, Devergne O (2004) Expression of IL-27 in human Th1-associated granulomatous diseases. J Pathol 202(2):164–171CrossRefPubMed
37.
Zurück zum Zitat Facco M, Cabrelle A, Teramo A, Olivieri V, Gnoato M, Teolato S, Ave E, Gattazzo C, Fadini GP, Calabrese F, Semenzato G, Agostini C (2011) Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax 66(2):144–150CrossRefPubMed Facco M, Cabrelle A, Teramo A, Olivieri V, Gnoato M, Teolato S, Ave E, Gattazzo C, Fadini GP, Calabrese F, Semenzato G, Agostini C (2011) Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax 66(2):144–150CrossRefPubMed
38.
Zurück zum Zitat Ramos-Casals M, Brito-Zerón P, Muñoz S, Soto MJ, BIOGEAS STUDY Group (2008) A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore) 87(6):345–364CrossRef Ramos-Casals M, Brito-Zerón P, Muñoz S, Soto MJ, BIOGEAS STUDY Group (2008) A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore) 87(6):345–364CrossRef
39.
Zurück zum Zitat Bargagli E, Olivieri C, Rottoli P (2011) Cytokine modulators in the treatment of sarcoidosis. Rheumatol Int 31(12):1539–1544CrossRefPubMed Bargagli E, Olivieri C, Rottoli P (2011) Cytokine modulators in the treatment of sarcoidosis. Rheumatol Int 31(12):1539–1544CrossRefPubMed
40.
Zurück zum Zitat Chen ES, Moller DR (2011) Sarcoidosis–scientific progress and clinical challenges. Nat Rev Rheumatol 7(8):457–467CrossRefPubMed Chen ES, Moller DR (2011) Sarcoidosis–scientific progress and clinical challenges. Nat Rev Rheumatol 7(8):457–467CrossRefPubMed
41.
Zurück zum Zitat Baughman RP, Strohofer SA, Buchsbaum J, Lower EE (1990) Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med 115(1):36–42PubMed Baughman RP, Strohofer SA, Buchsbaum J, Lower EE (1990) Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med 115(1):36–42PubMed
42.
Zurück zum Zitat Utz JP, Limper AH, Kalra S, Specks U, Scott JP, Vuk-Pavlovic Z, Schroeder DR (2003) Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 124(1):177–185CrossRefPubMed Utz JP, Limper AH, Kalra S, Specks U, Scott JP, Vuk-Pavlovic Z, Schroeder DR (2003) Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 124(1):177–185CrossRefPubMed
43.
Zurück zum Zitat Khanna D, Liebling MR, Louie JS (2003) Etanercept ameliorates sarcoidosis arthritis and skin disease. J Rheumatol 30(8):1864–1867PubMed Khanna D, Liebling MR, Louie JS (2003) Etanercept ameliorates sarcoidosis arthritis and skin disease. J Rheumatol 30(8):1864–1867PubMed
44.
Zurück zum Zitat Doty JD, Mazur JE, Judson MA (2005) Treatment of sarcoidosis with infliximab. Chest 127(3):1064–1071CrossRefPubMed Doty JD, Mazur JE, Judson MA (2005) Treatment of sarcoidosis with infliximab. Chest 127(3):1064–1071CrossRefPubMed
45.
Zurück zum Zitat Roberts SD, Wilkes DS, Burgett RA, Knox KS (2003) Refractory sarcoidosis responding to infliximab. Chest 124(5):2028–2031CrossRefPubMed Roberts SD, Wilkes DS, Burgett RA, Knox KS (2003) Refractory sarcoidosis responding to infliximab. Chest 124(5):2028–2031CrossRefPubMed
46.
Zurück zum Zitat Rossman MD, Newman LS, Baughman RP, Teirstein A, Weinberger SE, Miller W Jr, Sands BE (2006) A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 23(3):201–208PubMed Rossman MD, Newman LS, Baughman RP, Teirstein A, Weinberger SE, Miller W Jr, Sands BE (2006) A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 23(3):201–208PubMed
47.
Zurück zum Zitat Callejas-Rubio JL, Ortego-Centeno N, Lopez-Perez L, Benticuaga MN (2006) Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol 25(4):596–597CrossRefPubMed Callejas-Rubio JL, Ortego-Centeno N, Lopez-Perez L, Benticuaga MN (2006) Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol 25(4):596–597CrossRefPubMed
48.
Zurück zum Zitat Baughman RP, Lower EE, Drent M (2008) Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them. Sarcoidosis Vasc Diffuse Lung Dis 25(2):76–89PubMed Baughman RP, Lower EE, Drent M (2008) Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them. Sarcoidosis Vasc Diffuse Lung Dis 25(2):76–89PubMed
49.
Zurück zum Zitat Vigne C, Tebib JG, Pacheco Y, Coury F (2013) Sarcoidosis: an underestimated and potentially severe side effect of anti-TNF-alpha therapy. Joint Bone Spine 80(1):104–107CrossRefPubMed Vigne C, Tebib JG, Pacheco Y, Coury F (2013) Sarcoidosis: an underestimated and potentially severe side effect of anti-TNF-alpha therapy. Joint Bone Spine 80(1):104–107CrossRefPubMed
50.
Zurück zum Zitat Daïen CI, Monnier A, Claudepierre P, Constantin A, Eschard JP, Houvenagel E, Samimi M, Pavy S, Pertuiset E, Toussirot E, Combe B, Morel J (2009) Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Club Rhumatismes et Inflammation (CRI). Rheumatology (Oxford) 48(8):883–886CrossRef Daïen CI, Monnier A, Claudepierre P, Constantin A, Eschard JP, Houvenagel E, Samimi M, Pavy S, Pertuiset E, Toussirot E, Combe B, Morel J (2009) Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Club Rhumatismes et Inflammation (CRI). Rheumatology (Oxford) 48(8):883–886CrossRef
51.
Zurück zum Zitat Bosè F, Raeli L, Garutti C, Frigerio E, Cozzi A, Crimi M, Caprioli F, Scavelli R, Altomare G, Geginat J, Abrignani S, Reali E (2011) Dual role of anti-TNF therapy: enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissues. Clin Immunol 139(2):164–176CrossRefPubMed Bosè F, Raeli L, Garutti C, Frigerio E, Cozzi A, Crimi M, Caprioli F, Scavelli R, Altomare G, Geginat J, Abrignani S, Reali E (2011) Dual role of anti-TNF therapy: enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissues. Clin Immunol 139(2):164–176CrossRefPubMed
52.
Zurück zum Zitat Tong D, Manolios N, Howe G, Spencer D (2012) New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognised complication. Intern Med J 42(1):89–94CrossRefPubMed Tong D, Manolios N, Howe G, Spencer D (2012) New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognised complication. Intern Med J 42(1):89–94CrossRefPubMed
53.
Zurück zum Zitat Banse C, Bisson-Vaivre A, Kozyreff-Meurice M, Vittecoq O, Goëb V (2013) No impact of tumor necrosis-factor antagonists on the joint manifestations of sarcoidosis. Int J Gen Med 22(6):605–611CrossRef Banse C, Bisson-Vaivre A, Kozyreff-Meurice M, Vittecoq O, Goëb V (2013) No impact of tumor necrosis-factor antagonists on the joint manifestations of sarcoidosis. Int J Gen Med 22(6):605–611CrossRef
54.
Zurück zum Zitat Garg S, Garg K, Altaf M, Magaldi JA (2008) Refractory vertebral sarcoidosis responding to infliximab. J Clin Rheumatol 14(4):238–240CrossRefPubMed Garg S, Garg K, Altaf M, Magaldi JA (2008) Refractory vertebral sarcoidosis responding to infliximab. J Clin Rheumatol 14(4):238–240CrossRefPubMed
55.
Zurück zum Zitat Hasni SA, Kunz D, Finzel K, Gruber BL (2010) Osseous sarcoidosis treated with tumor necrosis factor-inhibitors: case report and review of the literature. Spine 35(18):E904–E907CrossRefPubMed Hasni SA, Kunz D, Finzel K, Gruber BL (2010) Osseous sarcoidosis treated with tumor necrosis factor-inhibitors: case report and review of the literature. Spine 35(18):E904–E907CrossRefPubMed
Metadaten
Titel
Osseous sarcoidosis: a case series
verfasst von
Halyna Kuzyshyn
David Feinstein
Sharon L. Kolasinski
Hala Eid
Publikationsdatum
01.05.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 5/2015
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-014-3170-4

Weitere Artikel der Ausgabe 5/2015

Rheumatology International 5/2015 Zur Ausgabe

Letter to the Editor - Food for Thought

Intranasal oxytocin and NSAIDs

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.